Hypothesizing that the major difference between the outcome of the vaccine in preclinical models and clinical trials is the high level of immune suppression in cancer patients, we began to develop models and MUC1 vaccines for cancer prevention in patients at risk; before immune suppression develops. Here, MUC1 is linked to cancer.